• ArriVent Biopharma announced Cancer Cell publication of Phase 1b firmonertinib results in previously untreated advanced EGFR PACC-mutant non-small cell lung cancer.
• The 240 mg dose achieved a 68% confirmed response rate, with median progression-free survival of 16.0 months.
• At 160 mg, the confirmed response rate was 43%, with median progression-free survival of 11.1 months.
• Among 17 patients with baseline brain metastases, the confirmed intracranial response rate reached 47%, including 41% complete responses.
• The global Phase 3 ALPACCA trial continues enrolling patients, comparing firmonertinib with osimertinib or afatinib as first-line treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-116736), on October 19, 2026, and is solely responsible for the information contained therein.